Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $563.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity changed N/A to $563.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $563.8 million for FY2025, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $563.8 million at Soleno Therapeutics, down from $599.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $599.9 million in Q3 2025, with the low at $318.1 million in Q1 2025.